Kenvue Inc. $KVUE Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its position in Kenvue Inc. (NYSE:KVUE) by 45.9% during the first quarter, HoldingsChannel reports. The firm owned 6,403,576 shares of the company’s stock after buying an additional 2,014,672 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Kenvue were worth $110,398,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Physician Wealth Advisors Inc. lifted its position in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC purchased a new position in shares of Kenvue in the 4th quarter valued at $26,000. MV Capital Management Inc. purchased a new stake in shares of Kenvue in the 4th quarter valued at about $28,000. Reflection Asset Management acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $32,000. Finally, SBI Securities Co. Ltd. increased its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $18.77 on Thursday. The company has a 50-day simple moving average of $17.60 and a 200-day simple moving average of $17.61. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The company has a market cap of $36.05 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.40 and a beta of 0.54. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. Kenvue’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.24 earnings per share. On average, equities analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.59% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Barclays reduced their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Finally, Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.